AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6605082 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 78
Study 6605082 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment and Surgical treatment
Number of subjects: 78
Study 29494458 — intervention group
Group type: EXPERIMENTAL
Intervention: Derotation connectors (D+ group)
Number of subjects: 68
Study 29494458 — intervention group
Group type: COMPARATOR
Intervention: No derotation connectors (D- group)
Number of subjects: 68
Study 29494458 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 26964825 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) at 125 mm Hg
Number of subjects: 580
Study 26964825 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) at 75 mm Hg
Number of subjects: 580
Study 26964825 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (leaving wounds open)
Number of subjects: 580
Study 23958073 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ-Blocker
Number of subjects: 40
Study 23958073 — intervention group
Group type: COMPARATOR
Intervention: Cohen Flex-Tip blocker
Number of subjects: 40
Study 22592556 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AP) at ST36
Number of subjects: 20
Study 22592556 — intervention group
Group type: COMPARATOR
Intervention: Sham-AP
Number of subjects: 20
Study 22592556 — intervention group
Group type: COMPARATOR
Intervention: No-AP
Number of subjects: 20
Study 21250566 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP containing cream applied for 3 minutes once per day during a 3-week treatment period
Number of subjects: 32
Study 21250566 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoride toothpaste (1450 ppm F- as NaF) and abstaining from other oral hygiene products
Number of subjects: 32
Study 18411019 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 149
Study 18411019 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 149
Study 15781506 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil (bolus doses of propofol 3-5 mg/kg and remifentanil 1-4 microg/kg)
Number of subjects: 21
Study 15781506 — intervention group
Group type: COMPARATOR
Intervention: Propofol with sevoflurane and nitrous oxide (propofol 3-5 mg/kg with 2%-8% sevoflurane and 70% nitrous oxide)
Number of subjects: 21
Study 15781506 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil
Number of subjects: 21
Study 15175435 — intervention group
Group type: EXPERIMENTAL
Intervention: IFL plus bevacizumab (5 mg/kg every two weeks)
Number of subjects: 813
Study 15175435 — intervention group
Group type: COMPARATOR
Intervention: IFL plus placebo
Number of subjects: 813
Study 11753186 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin plus clindamycin
Number of subjects: 18
Study 11753186 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin plus penicillin
Number of subjects: 18
Study 11753186 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin plus clindamycin or gentamicin plus penicillin
Number of subjects: 18
Study 9305487 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 424
Study 9305487 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily
Number of subjects: 424
Study 9305487 — intervention group
Group type: COMPARATOR
Intervention: Cisapride 10 mg four times daily
Number of subjects: 424
Study 9305487 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (both doses)
Number of subjects: 424
Study 9305487 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 424
Study 9305487 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 424
Study 9305487 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole vs Cisapride
Number of subjects: 424
Study 8351172 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush rods
Number of subjects: 50
Study 8351172 — intervention group
Group type: COMPARATOR
Intervention: AO plates
Number of subjects: 50
Study 3538987 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual buprenorphine 200 mcg
Number of subjects: 288
Study 3538987 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual buprenorphine 400 mcg
Number of subjects: 288
Study 3538987 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 288
Study 29471124 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vitamin D3 supplementation (400, 4000, or 10,000 IU)
Number of subjects: 0
Study 27405101 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed meat
Number of subjects: 0
Study 27405101 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole roasted pork (beheaded)
Number of subjects: 0
Study 27405101 — intervention group
Group type: COMPARATOR
Intervention: Living animal in meat advertisement
Number of subjects: 0
Study 27405101 — intervention group
Group type: EXPERIMENTAL
Intervention: Describing industrial meat production as 'harvesting'
Number of subjects: 0
Study 27405101 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing 'beef/pork' with 'cow/pig' in a restaurant menu
Number of subjects: 0
Study 24232133 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple port sites training (M group)
Number of subjects: 20
Study 24232133 — intervention group
Group type: COMPARATOR
Intervention: Single port site training (S group)
Number of subjects: 20
Study 23147684 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based clinical decision support with twice-monthly audits and printed management suggestions based on guideline-recommended blood pressure targets
Number of subjects: 830
Study 23147684 — intervention group
Group type: COMPARATOR
Intervention: Control group without audit and feedback decision support
Number of subjects: 830
Study 20850812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 19067936 — intervention group
Group type: EXPERIMENTAL
Intervention: School sex education
Number of subjects: 11825
Study 16408185 — intervention group
Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 60
Study 16408185 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Hysterectomy (VH)
Number of subjects: 60
Study 12645703 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (off-pump and on-pump)
Number of subjects: 81
Study 12645703 — intervention group
Group type: COMPARATOR
Intervention: CABG patients
Number of subjects: 81
Study 12645703 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG patients with cognitive decline
Number of subjects: 81
Study 10637462 — intervention group
Group type: EXPERIMENTAL
Intervention: IIEF-5 diagnostic test
Number of subjects: 1152
Study 8606331 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic arthritis (PA) group
Number of subjects: 90
Study 8606331 — intervention group
Group type: COMPARATOR
Intervention: Control (CO) group
Number of subjects: 90
Study 2082484 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 50 mg t.i.d.
Number of subjects: 927
Study 2082484 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole, 50 mg t.i.d. plus 75 mg t.i.d.
Number of subjects: 927
Study 2082484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study 117967 — intervention group
Group type: EXPERIMENTAL
Intervention: Total muscle protein breakdown
Number of subjects: 36
Study 117967 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of total muscle protein degraded
Number of subjects: 36
Study 117967 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein degradation in infants losing weight
Number of subjects: 36
Study 117967 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein degradation in infants gaining weight
Number of subjects: 36
Study 117967 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein degradation in infants who died within 2 weeks
Number of subjects: 36
Study 117967 — intervention group
Group type: COMPARATOR
Intervention: Myofibrillar protein breakdown
Number of subjects: 36
Study 30200118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent feeding with semi-solid nutrients (IS)
Number of subjects: 28
Study 27203279 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 460
Study 27203279 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 460
Study 24959618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil administration at 0.15 ng · mL(‐1) until extubation
Number of subjects: 0
Study 24959618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil administration
Number of subjects: 0
Study 24959618 — intervention group
Group type: COMPARATOR
Intervention: Normal saline administration (Control group)
Number of subjects: 0
Study 22851805 — intervention group
Group type: EXPERIMENTAL
Intervention: SB‐649868 (10, 30, 60 mg)
Number of subjects: 52
Study 22851805 — intervention group
Group type: EXPERIMENTAL
Intervention: SB‐649868 (60 mg)
Number of subjects: 52
Study 22851805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 20170699 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6mg daily
Number of subjects: 94
Study 20170699 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 20mg daily
Number of subjects: 94
Study 18945282 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based oily disinfectant gel containing 70% ethanol after regular hand washing
Number of subjects: 1431
Study 18945282 — intervention group
Group type: COMPARATOR
Intervention: Control DCCs (no alcohol-based hand-disinfection)
Number of subjects: 1431
Study 15832830 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with 100% adherence
Number of subjects: 1050
Study 15832830 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with at least 80% adherence
Number of subjects: 1050
Study 15832830 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with < 80% adherence
Number of subjects: 1050
Study 15832830 — intervention group
Group type: COMPARATOR
Intervention: Baseline QoL scores
Number of subjects: 1050
Study 12875727 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg CEE + 2 mg MPA + 1 tab Caltrate‐D per day (Group A)
Number of subjects: 236
Study 12875727 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg CEE + 2 mg MPA + 1 tab Caltrate‐D per day (Group B)
Number of subjects: 236
Study 12875727 — intervention group
Group type: COMPARATOR
Intervention: 1 tab Caltrate‐D per day (Group C)
Number of subjects: 236
Study 10606110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoxaparin (1 mg/kg bolus dose)
Number of subjects: 60
Study 10606110 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 60
Study 8542245 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus interferon
Number of subjects: 73
Study 8542245 — intervention group
Group type: COMPARATOR
Intervention: DTIC alone
Number of subjects: 73
Study 2145212 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with gamma-interferon (2 million units/m2)
Number of subjects: 81
Study 2145212 — intervention group
Group type: COMPARATOR
Intervention: Vaccine alone
Number of subjects: 81
Study 6990474 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 91
Study 6990474 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin
Number of subjects: 91
Study 6380897 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (100 mg suppositories)
Number of subjects: 30
Study 6380897 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg suppositories)
Number of subjects: 30
Study 6380897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30755574 — intervention group
Group type: EXPERIMENTAL
Intervention: I.V. Clonidine (2mcg/kg)
Number of subjects: 80
Study 30755574 — intervention group
Group type: COMPARATOR
Intervention: I.V. Fentanyl (2mcg/kg)
Number of subjects: 80
Study 30864768 — intervention group
Group type: EXPERIMENTAL
Intervention: ECA-Q (Embodied Conversational Agent for smoking cessation), 14-day program delivered through Tablet computers
Number of subjects: 6
Study 25345257 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer containing spent grain wax, Butyrospermum parkii extract, Argania spinosa kernel oil (S)
Number of subjects: 29
Study 25345257 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone cream (HC)
Number of subjects: 29
Study 22814367 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 396
Study 22814367 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 396
Study 22814367 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 396
Study 22814367 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tests for glucose abnormalities or CAD
Number of subjects: 396
Study 22814367 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean systolic blood pressure
Number of subjects: 396
Study 22814367 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean diastolic blood pressure
Number of subjects: 396
Study 22814367 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean total cholesterol
Number of subjects: 396
Study 22814367 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of patients with blood pressure below 140/90 mmHg
Number of subjects: 396
Study 22814367 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of patients with blood pressure below 130/80 mmHg
Number of subjects: 396
Study 20356485 — intervention group
Group type: COMPARATOR
Intervention: PCM group (pantoprazole 40 mg twice a day, clarithromycin 500 mg twice a day, metronidazole 400 mg twice a day for 7 days)
Number of subjects: 642
Study 20356485 — intervention group
Group type: EXPERIMENTAL
Intervention: PCM plus wenweishu group
Number of subjects: 642
Study 20356485 — intervention group
Group type: EXPERIMENTAL
Intervention: PCM plus yangweishu group
Number of subjects: 642
Study 17934599 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking stimulation using an orthodontic pacifier (Nuk)
Number of subjects: 95
Study 17934599 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking stimulation using a gloved finger
Number of subjects: 95
Study 17934599 — intervention group
Group type: COMPARATOR
Intervention: Control group (no non-nutritive sucking stimulation)
Number of subjects: 95
Study 16127252 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI imaging
Number of subjects: 191
Study 12693153 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 20
Study 12693153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20
Study 10446945 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 106
Study 10446945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 7841054 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐alpha 2c monotherapy (30 micrograms m‐2 s.c. twice weekly)
Number of subjects: 102
Study 7841054 — intervention group
Group type: COMPARATOR
Intervention: Combination of rIFN‐alpha 2c and rIFN‐gamma (30 micrograms m‐2 rIFN‐alpha 2c and 100 micrograms m‐2 rIFN‐gamma)
Number of subjects: 102
Study 2221590 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide, 400 micrograms daily for 1 yr
Number of subjects: 32
Study 2221590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2221590 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 32
Study 515535 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg of Ba 253 as metered aerosols
Number of subjects: 12
Study 515535 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of Ba 253 as metered aerosols
Number of subjects: 12
Study 515535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31947038 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exposure with randomized height changes and perturbations
Number of subjects: 0
Study 28082335 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (3.75 mg/Kg)
Number of subjects: 12
Study 28082335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28082335 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12
Study 25474535 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g every 6 hours for 3 days
Number of subjects: 40
Study 25474535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24499497 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001 (5, 7.5 or 10 mg)
Number of subjects: 440
Study 24499497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 22964494 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation digital flexible ureteroscope (Invisio D-URD; distal tip diameter = 8.7 Fr)
Number of subjects: 140
Study 22964494 — intervention group
Group type: COMPARATOR
Intervention: Old-generation fibre-optic flexible ureteroscope (DUR-8; distal tip diameter = 6.75 Fr)
Number of subjects: 140
Study 21577364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (500.0 mg/d)
Number of subjects: 51
Study 21577364 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (300.0 mg/d)
Number of subjects: 51
Study 17327309 — intervention group
Group type: EXPERIMENTAL
Intervention: High tertile of dairy calcium intake
Number of subjects: 259
Study 17327309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy calcium intake
Number of subjects: 259
Study 15610836 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg/hr
Number of subjects: 80
Study 15610836 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.6 mg/kg/hr
Number of subjects: 80
Study 15610836 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.9 mg/kg/hr
Number of subjects: 80
Study 15610836 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1.2 mg/kg/hr
Number of subjects: 80
Study 10746845 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol vaginal tablets (EVT)
Number of subjects: 96
Study 10746845 — intervention group
Group type: COMPARATOR
Intervention: Estriol vagitories (EV)
Number of subjects: 96
Study 8958490 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine (B)
Number of subjects: 52
Study 8958490 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine with diamorphine (BD)
Number of subjects: 52
Study 8958490 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine with midazolam (BM)
Number of subjects: 52
Study 8958490 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine with diamorphine and midazolam (BMD)
Number of subjects: 52
Study 8251890 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 622
Study 8251890 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan
Number of subjects: 622
Study 8251890 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN)
Number of subjects: 622
Study 8251890 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 622
Study 3092610 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg glyceryl trinitrate (GTN) transdermal patches for 6 hours during exercise
Number of subjects: 12
Study 3092610 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg glyceryl trinitrate (GTN) transdermal patches for 6 hours during sauna
Number of subjects: 12
Study 3092610 — intervention group
Group type: COMPARATOR
Intervention: Control day (no intervention)
Number of subjects: 12
Study 30442276 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ‐5D‐3L (adult perspective)
Number of subjects: 0
Study 30442276 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ‐5D‐Y (child perspective)
Number of subjects: 0
Study 30442276 — intervention group
Group type: COMPARATOR
Intervention: C‐TTO responses
Number of subjects: 0
Study 30442276 — intervention group
Group type: COMPARATOR
Intervention: DCE + death valuations
Number of subjects: 0
Study 29622823 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 8 weeks
Number of subjects: 12
Study 29622823 — intervention group
Group type: COMPARATOR
Intervention: Conventional care only (Control Group)
Number of subjects: 12
Study 25668238 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol + Spironolactone
Number of subjects: 23
Study 25668238 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol
Number of subjects: 23
Study 25668238 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 23
Study 25668238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23266440 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive-behavioral weight loss program with telephone counseling and tailored newsletters
Number of subjects: 693
Study 23266440 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 693
Study 21216318 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory seasonal influenza vaccine program
Number of subjects: 2443
Study 18305062 — intervention group
Group type: EXPERIMENTAL
Intervention: alemtuzumab, 30 mg i.v. over 2 hours three times per week on alternate days for a maximum of 12 weeks
Number of subjects: 297
Study 18305062 — intervention group
Group type: COMPARATOR
Intervention: chlorambucil, 40 mg/m(2) orally every 28 days for a maximum of 12 months
Number of subjects: 297
Study 16564618 — intervention group
Group type: EXPERIMENTAL
Intervention: Active motor tDCS (2mA, 20 min for 5 consecutive days)
Number of subjects: 0
Study 16564618 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 12547477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (up to 45 mg/day)
Number of subjects: 29
Study 12547477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12547477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 29
Study 10711525 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic warfarin sodium product (Barr Laboratories)
Number of subjects: 210
Study 10711525 — intervention group
Group type: COMPARATOR
Intervention: Coumadin (Dupont Pharma)
Number of subjects: 210